Showing results (41-50 of 57) with videos related to
Sort By:
Pageof 6
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 15, 2012
Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stentsHanim Sen, Kenneth Tandjung, Mounir W Z Basalus, et al.Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|August 24, 2010
TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectivesM W Z Basalus, K Tandjung, K G van Houwelingen, et al.The American Journal of Cardiology|September 4, 2012
Comparison of frequency of periprocedural myocardial infarction in patients with and without diabetes mellitus to those with previously unknown but elevated glycated hemoglobin levels (from the TWENTE Trial)Kenneth Tandjung, K Gert van Houwelingen, Hanneke Jansen, et al.Journal of the American Heart Association|February 1, 2018
Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting StentsLiefke C van der Heijden, Marlies M Kok, Paolo Zocca, et al.JAMA Cardiology|January 24, 2017
Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical TrialClemens von Birgelen, Liefke C van der Heijden, Mounir W Z Basalus, et al.JACC. Cardiovascular Interventions|March 8, 2016
Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS TrialsMarlies M Kok, Liefke C van der Heijden, Hanim Sen, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 21, 2014
Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trialHanim Sen, Ming Kai Lam, Kenneth Tandjung, et al.European Heart Journal Open|November 13, 2025
Complex all-comers and patients with diabetes and prediabetes treated with Xience Sierra everolimus-eluting stents: COASTLINE high-riskDaphne van Vliet, Eline H Ploumen, Tineke H Pinxterhuis, et al.Journal of the American College of Cardiology|February 21, 2012
A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trialClemens von Birgelen, Mounir W Z Basalus, Kenneth Tandjung, et al.Journal of the American College of Cardiology|April 23, 2013
Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trialKenneth Tandjung, Hanim Sen, Ming Kai Lam, et al.Pageof 6